Docosahexaenoic酸 (DHA) looks promising on paper. It’s an omega-3 fatty acid abundant in mackerel, sardines, other oily fish. The theory is sound: it supports connections between brain cells. Cognitive function improves. Dementia gets stalled.
But theory is one thing. Evidence is another.
For years, no one could prove DHA from supplements actually reached the brain or did anything useful once there. Now, that ambiguity is gone. A USC research team just published the results of a rigorous, two-year trial. The headline? High-dose DHA reaches the brain. It just doesn’t help you think. Or remember.
DHA Got There, But Didn’t Stick
The study followed 365 people aged 55 to 80. Older adults with little fish in their diets. Half of them carried the APOE ε4 gene. That’s the heavy hitter for late-onset Alzheimer’s risk. All of them consumed less than 200 milligrams of DHA daily. A pittance compared to the treatment.
Researchers split the group. One got a massive daily hit—2,000 milligrams—of DHA for 24 months.
The others got placebo. Corn oil mixed with soybean oil. Tasted identical. Looked identical. No one knew who was what.
First order of business: prove delivery.
They measured cerebrospinal fluid. The fluid bathing the brain. After six months, DHA concentrations in the treatment group jumped by 17%. It didn’t matter if you had the risk gene. The stuff got in. Direct evidence that supplements cross the barrier.
“Everyone hopes for a silver bullet,” says Hussein Naji Yassine. “But we can’t say fish oil supplements protect brain health.”
Then they waited two full years. And measured.
Participants took the Repeatable Battery for the Assessment. Standard memory tests. The DHA group and placebo group were identical. No difference in performance. They scanned brains, too. Checked the hippocampus—the memory hub. Checked for shrinkage. Again. Nothing.
Hippocampal volume didn’t change. Memory didn’t improve. The supplement did nothing visible.
So Why Fail?
This is where the science gets messy. DHA arrived. Why no victory?
Maybe the brain broke it down. There’s an enzyme called cPLA2. Calcium-dependent phospholipase. It might degrade DHA before it ever makes it into synaptic membranes. Where the magic is supposed to happen. If the structure dissolves before it builds. Pointless.
Maybe it was inflammation. Many participants were overweight. Hypertensive. Sedentary. Chronic inflammation floods the system. It masks subtle benefits. Can a single nutrient fight that fire? Probably not.
Or maybe it’s timing.
Average age? Sixty-six. That’s relatively young in Alzheimer’s terms. Over two years, most people just stayed healthy. There wasn’t enough decline to stop. How do you prevent a fall from a ten-foot wall when nobody fell?
The open question isn’t whether DHA travels. We know that now. It’s whether the brain still wants it, or if we’re trying to patch a hole that’s already closed.
